Drugs / Treatment Period 1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05768919 Background | Mar 2023 → Feb 2026 overdue | glioblastoma | SignPath Pharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treatment Period 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768919 ↗ |
| Known as | TMZ | “Temozolomide (TMZ)” NCT05768919 ↗ |
| Route | Oral | “Dose: 75 mg/m2 Route: Oral” NCT05768919 ↗ |